mefenamic acid has been researched along with Disease Models, Animal in 18 studies
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment regimen used in this study is within the range for which mefenamic acid has been used in clinical practice, thus, it is demonstrated the capacity of mefenamic acid to act as a potent anti-schistosomal agent suitable for clinical repurposing in the treatment of schistosomiasis." | 7.91 | Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. ( Andricopulo, AD; Carnaúba, PU; de Moraes, J; Ferreira, LLG; Lago, EM; Mazloum, SF; Pinto, PL; Queiroz, TG; Rocha, JA; Rodrigues, VC; Silva, MP, 2019) |
| "Mefenamic acid is a non-steroidal anti-inflammatory drug able to control the symptoms of osteoarthritis (OA), but its effects on protection of cartilage and bone are still unclear." | 7.83 | Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis. ( Aguiar, GC; Amaral, FA; Caliari, MV; Ferreira, AJ; Queiroz-Junior, CM; Sitta, GL; Teixeira, MM, 2016) |
| " Enhanced analgesic and anti-inflammatory activity was observed with S-SMEDD formulations in acetic acid-induced writhings and carrageenan-induced paw edema models, respectively." | 3.91 | Mefenamic acid-loaded solid SMEDDS: an innovative aspect for dose reduction and improved pharmacodynamic profile. ( Bedi, N; Kumar, M; Singh, D, 2019) |
| "The treatment regimen used in this study is within the range for which mefenamic acid has been used in clinical practice, thus, it is demonstrated the capacity of mefenamic acid to act as a potent anti-schistosomal agent suitable for clinical repurposing in the treatment of schistosomiasis." | 3.91 | Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. ( Andricopulo, AD; Carnaúba, PU; de Moraes, J; Ferreira, LLG; Lago, EM; Mazloum, SF; Pinto, PL; Queiroz, TG; Rocha, JA; Rodrigues, VC; Silva, MP, 2019) |
| "Mefenamic acid is a non-steroidal anti-inflammatory drug able to control the symptoms of osteoarthritis (OA), but its effects on protection of cartilage and bone are still unclear." | 3.83 | Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis. ( Aguiar, GC; Amaral, FA; Caliari, MV; Ferreira, AJ; Queiroz-Junior, CM; Sitta, GL; Teixeira, MM, 2016) |
| "A series of new tetrasubstituted thiophenes (4a-4i, 5a-5i and 6a-6f) have been synthesized as novel anti-inflammatory agents and were evaluated for their anti-inflammatory activity in carrageenin-induced rat hind paw oedema model at the doses of 10, 20 and 40mg/kg body weight." | 3.74 | Syntheses of new tetrasubstituted thiophenes as novel anti-inflammatory agents. ( Haque, N; Molvi, KI; Sudarsanam, V; Vasu, KK; Yerande, SG, 2007) |
| "The dose-response relation of S-methylisothiourea, rofecoxib, mefenamic acid, and their combination was studied in the late phase of formalin-induced pain in mice over the time spent in licking the hindpaw after formalin injection." | 3.74 | The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study. ( Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2008) |
| "Ibuprofen was more effective against the primary generalized model." | 1.27 | Attenuation of penicillin models of epilepsy by nonsteroidal anti-inflammatory drugs. ( Wallenstein, MC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (44.44) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Stock, N | 1 |
| Munoz, B | 1 |
| Wrigley, JD | 1 |
| Shearman, MS | 1 |
| Beher, D | 1 |
| Peachey, J | 1 |
| Williamson, TL | 1 |
| Bain, G | 1 |
| Chen, W | 1 |
| Jiang, X | 1 |
| St-Jacques, R | 1 |
| Prasit, P | 1 |
| Molvi, KI | 1 |
| Vasu, KK | 1 |
| Yerande, SG | 1 |
| Sudarsanam, V | 1 |
| Haque, N | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Aguiar, GC | 1 |
| Queiroz-Junior, CM | 1 |
| Sitta, GL | 1 |
| Amaral, FA | 1 |
| Teixeira, MM | 1 |
| Caliari, MV | 1 |
| Ferreira, AJ | 1 |
| Kumar, M | 1 |
| Singh, D | 1 |
| Bedi, N | 1 |
| Lago, EM | 1 |
| Silva, MP | 1 |
| Queiroz, TG | 1 |
| Mazloum, SF | 1 |
| Rodrigues, VC | 1 |
| Carnaúba, PU | 1 |
| Pinto, PL | 1 |
| Rocha, JA | 1 |
| Ferreira, LLG | 1 |
| Andricopulo, AD | 1 |
| de Moraes, J | 1 |
| Moradi, A | 1 |
| Navidpour, L | 1 |
| Amini, M | 1 |
| Sadeghian, H | 1 |
| Shadnia, H | 1 |
| Firouzi, O | 1 |
| Miri, R | 1 |
| Ebrahimi, SE | 1 |
| Abdollahi, M | 1 |
| Zahmatkesh, MH | 1 |
| Shafiee, A | 1 |
| Guitton, MJ | 1 |
| Caston, J | 1 |
| Ruel, J | 1 |
| Johnson, RM | 1 |
| Pujol, R | 1 |
| Puel, JL | 1 |
| Bhat, AS | 1 |
| Tandan, SK | 1 |
| Kumar, D | 1 |
| Krishna, V | 1 |
| Prakash, VR | 1 |
| Adachi, K | 1 |
| Wax, J | 1 |
| Tessman, DK | 1 |
| Winder, CV | 1 |
| Stephens, MD | 1 |
| Carlton, WW | 1 |
| Engelhardt, JA | 1 |
| DeLeo, JA | 1 |
| Colburn, RW | 1 |
| Coombs, DW | 1 |
| Ellis, MA | 1 |
| Cryer, HM | 1 |
| Unger, LS | 1 |
| Garrison, RN | 1 |
| Harris, PD | 1 |
| Wallenstein, MC | 1 |
| Mörsdorf, K | 1 |
| Anspach, K | 1 |
| Wawrzyńska-Pagowska, J | 1 |
| Willoughby, DA | 1 |
| DiRosa, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nitrous Oxide as Treatment for Tinnitus: A Randomized Crossover Trial[NCT03365011] | Phase 4 | 40 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change of participant-reported tinnitus symptoms 1 week after each intervention.~The Tinnitus Functional Index (TFI) is a 25-question survey assessing tinnitus impact on quality of life. Participants were asked to rate on a scale from 0-10 the degree of unpleasantness, cognitive interference, sleep disturbance, auditory difficulties, interference with relaxation, and emotional distress associated with their tinnitus. Subscores are summed and scaled to a score of 0-100. A score less than 25 indicates mild problems due to tinnitus and little need for intervention, while a score between 25-50 indicates significant problems due to tinnitus with potential need for intervention.~A decrease in TFI score indicates decreased bother due to tinnitus over time, a better outcome. An increase in TFI score indicates increased bother due to tinnitus over time, a worse outcome." (NCT03365011)
Timeframe: Pre-intervention and 1 week post-intervention
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | -1.8 |
| Nitrous Oxide | -2.5 |
"Change in participant-reported tinnitus bother after each intervention.~Global Bothersome Scale (GBS) measured participant's self-assessment of tinnitus bother on a 5-point scale ranging from Not bothered, 0 to Extremely bothered, 5.~A change of 0 indicates no change in tinnitus bother over time. A change of -1 indicates somewhat improved tinnitus bother, and a change of positive 1 indicates somewhat worsened tinnitus bother. A change of positive 2 indicates significantly worsened tinnitus bother." (NCT03365011)
Timeframe: Pre-intervention and 1 week post-intervention
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Somewhat improved, -1 | No change, 0 | Somewhat worsened, 1 | Significantly worsened, 2 | |
| Nitrous Oxide | 2 | 34 | 2 | 0 |
| Placebo | 5 | 28 | 5 | 1 |
1 review available for mefenamic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Clinical use of non-steroid anti-inflammatory agents].
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arthritis, Rheumatoid; Aspirin; Cell Mi | 1974 |
17 other studies available for mefenamic acid and Disease Models, Animal
| Article | Year |
|---|---|
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2006 |
Syntheses of new tetrasubstituted thiophenes as novel anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship | 2007 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Cartilage; Disease Models, Animal; | 2016 |
Mefenamic acid-loaded solid SMEDDS: an innovative aspect for dose reduction and improved pharmacodynamic profile.
Topics: Acetic Acid; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Avai | 2019 |
Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship | 2019 |
Design and synthesis of 2-phenoxynicotinic acid hydrazides as anti-inflammatory and analgesic agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2010 |
Salicylate induces tinnitus through activation of cochlear NMDA receptors.
Topics: Action Potentials; Animals; Behavior, Animal; Cochlea; Cochlear Nerve; Conditioning, Classical; Cycl | 2003 |
The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study.
Topics: Animals; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2008 |
A device for automatic measurement of writhing and its application to the assessment of analgesic agents.
Topics: Acetates; Acetic Acid; Aminopyrine; Analgesics; Animals; Behavior, Animal; Caffeine; Disease Models, | 1994 |
A sensitive method for the comparative bioassay of nonsteroidal anti-inflammatory compounds in adjuvant-induced primary inflammation in the rat.
Topics: Aminopyrine; Analysis of Variance; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin | 1975 |
Experimental renal papillary necrosis in the Syrian hamster.
Topics: Acetaminophen; Animals; Cricetinae; Disease Models, Animal; Ethylamines; Indomethacin; Kidney Medull | 1989 |
The differentiation of NSAIDs and prostaglandin action using a mechanical visceral pain model in the rat.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Models, Animal; Dose-Re | 1989 |
Prostaglandins maintain renal microvascular blood flow during hyperdynamic bacteremia.
Topics: Animals; Arterioles; Disease Models, Animal; Escherichia coli Infections; Male; Mefenamic Acid; Micr | 1988 |
Attenuation of penicillin models of epilepsy by nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arachidonic Acids | 1987 |
[Efficacy of different antiphlogistic agents with respect to carrageenan-inflammation, compared with other models of inflammation].
Topics: Adrenocorticotropic Hormone; Aminopyrine; Animals; Anti-Inflammatory Agents; Aspirin; Carrageenan; D | 1971 |
Studies on the mode of action of non-steroid anti-inflammatory drugs.
Topics: Animals; Aspirin; Cell Movement; Disease Models, Animal; Indomethacin; Inflammation; Leukocytes; Mef | 1972 |